Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20243643 | 0.86 | CYP1A2 (0.48) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL19872020 | 0.82 | ALDH1A1 (0.56) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL21505038 | 0.80 | ALDH1A1 (0.51) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL7593903 | 0.80 | TDP1 (0.62) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL21814399 | 0.79 | ALDH1A1 (0.51) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL21505040 | 0.79 | TDP1 (0.46) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL23789618 | 0.79 | ALDH1A1 (0.52) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL22486487 | 0.79 | TDP1 (0.78) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| SCHEMBL18074878 | 0.78 | CYP1A2 (0.63) | TDP1CYP1A2ADRB2ADRB1CYP3A4 | |
| Timolol SCHEMBL4912 | 0.78 | CYP1A2 (1.00) | TDP1CYP1A2ADRB2ADRB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| EP-2964224-B1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-10-17 | — | — | US | disclosed |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20210405280-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ALLERGAN SALES LLC (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021237096-A1 | DURABLE IMPLANTS AND MICROPARTICLES FOR LONG-TERM OCULAR THERAPY | Graybug Vision, Inc. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200129520-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ALLERGAN SALES LLC (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200123322-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | POLYACTIVA PTY LTD (AU) | 2020-04-23 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2019185543-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TIMOLOL | NOVALIQ GMBH (DE) | 2019-10-03 | — | — | WO | disclosed |
| US-20180064720-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ALLERGAN SALES LLC (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180064721-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ALLERGAN SALES LLC (US) | 2018-03-08 | — | — | US | disclosed |
| US-9907801-B1 | Combination of brimonidine and timolol for topical ophthalmic use | ALLERGAN SALES, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9907802-B1 | Combination of brimonidine and timolol for topical ophthalmic use | ALLERGAN SALES, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9770453-B2 | Combination of brimonidine and timolol for topical ophthalmic use | ALLERGAN SALES, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170157138-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ALLERGAN SALES LLC (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064720-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ADRB2, ADRA2B, PDE3B | TDP1 1779/4885CYP1A2 369/4885ADRB2 1/4885 |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | TDP1 4630/4885CYP1A2 3413/4885ADRB2 2941/4885 |
| US-20200123322-A1 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | ADRB3, PTGER3, CHRNE | TDP1 3114/4885CYP1A2 101/4885ADRB2 13/4885 |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | TDP1 564/4885CYP1A2 2699/4885ADRB2 669/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | TDP1 564/4885CYP1A2 2699/4885ADRB2 669/4885 |
| US-20170157138-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ADRB2, ADRA2B, PDE3B | TDP1 1779/4885CYP1A2 369/4885ADRB2 1/4885 |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | CHMP4B, EXOSC9, EXOSC5 | TDP1 1048/4885CYP1A2 2730/4885ADRB2 1066/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | TDP1 1048/4885CYP1A2 2730/4885ADRB2 1066/4885 |
| US-20200129520-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ADRB2, ADRA2B, PDE3B | TDP1 1779/4885CYP1A2 369/4885ADRB2 1/4885 |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | ADRB3, PTGER3, CHRM3 | TDP1 2961/4885CYP1A2 94/4885ADRB2 16/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | TDP1 4630/4885CYP1A2 3413/4885ADRB2 2941/4885 |
| US-20180064721-A1 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE | ADRB2, ADRA2B, PDE3B | TDP1 1779/4885CYP1A2 369/4885ADRB2 1/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | TDP1 4864/4885CYP1A2 2879/4885ADRB2 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.